# Orthobiologics use blood or marrow, while some use fat or donated tissue

*What Studies Say | Biologic Therapy Gilbert*

> Biologic therapy Gilbert research explained without the college paper: what may ease soreness and what studies haven't proved.

Do orthobiologics always make a sore joint feel better? No. These treatments use your arm-drawn blood, pelvic marrow, body fat, or tissue from a donor. Most of the useful research has studied knees.

Some people reported less soreness and easier movement afterward. Others felt much the same after saline or an ordinary steroid shot. One good report can't predict what you'll feel. The studies can only show what happened to groups of people.

## Less soreness doesn't prove joint repair

A treatment may ease soreness without rebuilding a worn joint. Studies haven't shown steady cartilage growth on an MRI. Easier movement still matters in daily life. It just doesn't mean the joint became new again.

Check whether a study measured soreness, movement, or the joint itself. See whether those people had trouble like yours. Knee results tell you little about a sore hip. Your exam still matters more than a broad claim.

## Taking marrow or fat hasn't meant more relief

Studies with more people haven't found that harder procedures always help more. One large study compared marrow, fat, and donated tissue with a steroid shot. The groups reported similar knee soreness and movement afterward. Many PRP and BMAC studies have also found similar results.

Some smaller studies favored marrow, and study methods weren't all alike. The people, prepared material, and follow-up times also differed. Compare possible relief with pelvic soreness, recovery, cost, and return visits. Those facts belong together before you decide.

## Your exam matters more than a sales claim

Use gentle movement and ease back on the activity causing soreness. Heat or ice may help when either feels good. It's reasonable to get an exam when the joint limits normal life. Don't let a bold promise replace that exam.

Joint preservation means trying care that may help you keep using the joint and delay surgery. It doesn't mean further wear will stop. QC Kinetix provides regenerative treatment options such as PRP made from spun blood, and its medical providers are clinicians who examine you before discussing knee or hip surgery alternatives.

## Sources

1. The 2025 Cochrane review of stem cell injections for knee osteoarthritis pooled 25 randomised trials (1,341 participants) and found that, compared with placebo injection, stem cell injection MAY slightly improve pain (1.2 points better on a 0-10 scale, 7 studies, 445 participants) and function (14.2 points better on a 0-100 scale, 7 studies, 432 participants) up to six months - both rated LOW-certainty evidence, downgraded for indirectness (cell source, preparation and dose varied across studies) and suspected publication bias, since up to three larger RCTs were conducted and withdrawn before reporting results. Radiographic progression was not assessed in any included study.
   Whittle SL, et al. — [Stem cell injections for osteoarthritis of the knee.](https://pubmed.ncbi.nlm.nih.gov/40169165/). *Cochrane Database of Systematic Reviews*, 2025. DOI: 10.1002/14651858.CD013342.pub2.
2. The largest head-to-head trial of cell-based orthobiologics to date randomised 480 patients with KL II-IV knee OA across four arms: autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, allogeneic umbilical cord tissue-derived MSCs, and a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another or to the corticosteroid control on either co-primary endpoint (VAS pain, KOOS pain), and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events were reported.
   Mautner K, et al. — [Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.](https://pubmed.ncbi.nlm.nih.gov/37919438/). *Nature Medicine*, 2023. DOI: 10.1038/s41591-023-02632-w.
3. The companion ESSKA-ORBIT consensus on cell-based therapy (77 experts, 22 countries, 27 statements) found only 5 of 27 statements reached recommendation level A or B; 22 were rated C or D. It concluded that cell-based therapy shows clinical benefit in pain and function up to 12 months for KL grades 1-3 with some benefit in selected KL 4, but that because of limited high-quality studies and NO clear superiority over other injectables it should be considered a SECOND-LINE option, after other non-operative treatment fails.
   de Girolamo L, et al. — [The use of injectable orthobiologics for knee osteoarthritis: A formal ESSKA-ORBIT consensus. Part 2-Cell-based therapy.](https://pubmed.ncbi.nlm.nih.gov/40923345/). *Knee Surgery, Sports Traumatology, Arthroscopy*, 2025. DOI: 10.1002/ksa.70001.
4. A meta-analysis of 27 Level I studies (1,042 PRP, 226 BMAC, 1,128 HA patients) found significantly better post-injection WOMAC, VAS and subjective IKDC scores for BOTH PRP and BMAC compared with hyaluronic acid - and NO significant difference between PRP and BMAC on any outcome score. This is the clearest published statement that the two most-marketed orthobiologics perform the same as each other in the knee.
   Belk JW, et al. — [Patients With Knee Osteoarthritis Who Receive Platelet-Rich Plasma or Bone Marrow Aspirate Concentrate Injections Have Better Outcomes Than Patients Who Receive Hyaluronic Acid: Systematic Review and Meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/36913992/). *Arthroscopy*, 2023. DOI: 10.1016/j.arthro.2023.03.001.
5. A randomized trial allocated 175 patients with KL II-IV knee OA to BMAC (n=111), PRP (n=34) or hyaluronic acid (n=30) and followed them for 12 months. All three produced significant improvement from baseline in WOMAC, KOOS and IKDC with no serious side effects; BMAC showed significantly better clinical improvement than PRP and HA on most scores, and PRP scored higher than HA without reaching statistical significance. Note the unequal, non-blinded design - this is the strongest direct BMAC-versus-PRP randomized comparison available, and it is not a strong design.
   Dulic O, et al. — [Bone Marrow Aspirate Concentrate versus Platelet Rich Plasma or Hyaluronic Acid for the Treatment of Knee Osteoarthritis.](https://pubmed.ncbi.nlm.nih.gov/34833411/). *Medicina (Kaunas)*, 2021. DOI: 10.3390/medicina57111193.
6. In a within-patient placebo-controlled trial, 25 people with BILATERAL knee osteoarthritis received bone marrow aspirate concentrate in one knee and saline in the other, acting as their own controls. Pain scores fell significantly from baseline in BOTH knees at 1 week, 3 months and 6 months, and the relief - described by the authors as dramatic - did not differ significantly between the BMAC knee and the saline knee.
   Shapiro SA, et al. — [A Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis.](https://pubmed.ncbi.nlm.nih.gov/27566242/). *American Journal of Sports Medicine*, 2017. DOI: 10.1177/0363546516662455.
7. A meta-analysis of 6 RCTs (860 patients, 334 receiving BMAC) found overall complication rates of 41.91% for BMAC versus 41.25% for comparator injectables (P=0.85), with knee effusion the commonest BMAC complication at 18.26%. Early and late complication rates did not differ significantly from HA, steroids, PRP, SVF, MSC or saline. The number needed to harm for BMAC relative to other injections was 152.
   Fucaloro S, et al. — [Complication rates of bone marrow aspirate concentrate injections versus other injectable therapies for knee osteoarthritis: A systematic review and meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/39473874/). *Journal of Orthopaedics*, 2025. DOI: 10.1016/j.jor.2024.10.005.
8. A randomized controlled trial compared a SINGLE ultrasound-guided injection of leukocyte-rich PRP (n=30) with micro-fragmented adipose tissue (n=28) in KL 1-4 knee OA. Both groups improved clinically meaningfully from baseline, and there was no significant difference in the primary outcome (KOOS-Pain at 6 months: 80.38 vs 81.61; P=.67) or in any other score - despite MFAT requiring a lipoaspiration procedure and PRP requiring only a blood draw.
   Baria M, et al. — [Platelet-Rich Plasma Versus Microfragmented Adipose Tissue for Knee Osteoarthritis: A Randomized Controlled Trial.](https://pubmed.ncbi.nlm.nih.gov/36147791/). *Orthopaedic Journal of Sports Medicine*, 2022. DOI: 10.1177/23259671221120678.
9. A systematic review of 33 clinical studies of minimally manipulated adipose tissue products for knee OA - of which only 7 were randomized - meta-analysed the 5 RCTs that compared adipose products directly with PRP and found COMPARABLE results between them. The authors explicitly flagged the limits of the literature: few high-level trials and overall low quality.
   Veronesi F, et al. — [Adipose Tissue-Derived Minimally Manipulated Products versus Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Systematic Review of Clinical Evidence and Meta-Analysis.](https://pubmed.ncbi.nlm.nih.gov/38202074/). *Journal of Clinical Medicine*, 2023. DOI: 10.3390/jcm13010067.
10. A phase III double-blind placebo-controlled trial of a SINGLE injection of culture-expanded autologous adipose-derived MSCs in 261 patients with KL grade 3 knee OA found significantly better VAS pain (25.2 vs 15.5 mm improvement; P=.004) and total WOMAC (21.7 vs 14.3; P=.002) at 6 months versus placebo, with no serious treatment-related adverse events - but MRI showed NO significant difference in cartilage-defect change between groups. Culture-expanded cells of this kind are a drug in the United States and are not available outside a trial.
   Kim KI, et al. — [Clinical Efficacy and Safety of the Intra-articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial.](https://pubmed.ncbi.nlm.nih.gov/37345256/). *American Journal of Sports Medicine*, 2023. DOI: 10.1177/03635465231179223.
11. The ADIPOA2 phase 2b trial randomised 135 patients with mild-to-moderate knee OA to low-dose (2 million) or high-dose (10 million) culture-expanded autologous adipose-derived stromal cells or saline placebo. At 6 months 47.3% of ADSC patients were OARSI/OMERACT strict responders versus 54.8% on placebo (relative risk 0.86; P=.46), and no secondary outcome differed significantly. A single injection of expanded adipose stromal cells did NOT improve pain or function versus saline.
   Pers YM, et al. — [Effect of intra-articular adipose-derived mesenchymal stromal cell versus placebo injection on pain and function in patients with knee osteoarthritis: the ADIPOA2 phase 2b randomised clinical trial.](https://pubmed.ncbi.nlm.nih.gov/40885690/). *Annals of the Rheumatic Diseases*, 2025. DOI: 10.1016/j.ard.2025.07.026.
12. A phase I/II randomized trial (n=26) compared hyaluronic acid with a single or a repeated dose of culture-expanded umbilical cord-derived MSCs. Only the MSC-treated patients improved significantly from baseline, and the repeated-dose group had significantly lower WOMAC pain (1.1 vs 4.3; P=.04) and VAS pain (2.4 vs 22.1; P=.03) than HA at 12 months. No MRI differences were detected and the trial is very small - it is hypothesis-generating, not practice-changing.
   Matas J, et al. — [Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial.](https://pubmed.ncbi.nlm.nih.gov/30592390/). *Stem Cells Translational Medicine*, 2019. DOI: 10.1002/sctm.18-0053.
13. A JBJS systematic review screened 420 papers on intra-articular cellular therapy for knee OA and focal cartilage defects and found only SIX studies at Level III evidence or higher, covering 300 knees, with wide variation in cell source, cell characterisation, adjuvant therapy and outcome assessment. All six reported improvement and no major adverse events, but the authors concluded the improvement was modest, a placebo effect could not be disregarded, and no consensus exists on indications, cell sources, preparation or delivery.
   Chahla J, Piuzzi NS, et al. — [Intra-Articular Cellular Therapy for Osteoarthritis and Focal Cartilage Defects of the Knee: A Systematic Review of the Literature and Study Quality Analysis.](https://pubmed.ncbi.nlm.nih.gov/27655978/). *Journal of Bone and Joint Surgery (American)*, 2016. DOI: 10.2106/JBJS.15.01495.
14. A multicenter prospective crossover randomized trial randomised 40 patients with discogenic chronic low back pain to a saline trigger-point control, intradiscal PRP, or intradiscal bone marrow concentrate, with crossover permitted for non-responders. Both PRP and BMC produced statistically significant improvement in pain and function with no adverse events, hospitalisations or surgery at 12 months - but ALL placebo patients reported under 50% relief and crossed over, and the trial was small and open-label.
   Navani A, et al. — [The Safety and Effectiveness of Orthobiologic Injections for Discogenic Chronic Low Back Pain: A Multicenter Prospective, Crossover, Randomized Controlled Trial with 12 Months Follow-up.](https://pubmed.ncbi.nlm.nih.gov/38285032/). *Pain Physician*, 2024.
15. A multicenter single-blind RCT randomised 200 patients 1:1:1 to a single injection of saline, hyaluronic acid or amniotic suspension allograft. ASA produced significant KOOS and VAS improvements maintained through 12 months with a 63.2% OMERACT-OARSI responder rate, no radiographic differences, and no concerning immunoglobulin or anti-HLA responses. Adverse events with ASA were comparable to HA, while NO treatment-emergent adverse events were reported in the saline group.
   Gomoll AH, et al. — [Safety and Efficacy of an Amniotic Suspension Allograft Injection Over 12 Months in a Single-Blinded, Randomized Controlled Trial for Symptomatic Osteoarthritis of the Knee.](https://pubmed.ncbi.nlm.nih.gov/33716121/). *Arthroscopy*, 2021. DOI: 10.1016/j.arthro.2021.02.044.
16. FDA's July 2020 final guidance 'Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use' is the document that decides whether a given orthobiologic can be used without a licence: an HCT/P may be regulated solely under section 361 only if it is minimally manipulated AND intended for homologous use, among other criteria; otherwise it is a drug or biological product requiring an approved licence or an active investigational new drug application.
   U.S. Food and Drug Administration — [Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use - Guidance for Industry and Food and Drug Administration Staff](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal). *FDA Guidance Document*, 2020.

## Bring the questions that matter to you

Bring the name of your sore joint and when it bothers you. Add old images and a list of medicines. QC Kinetix can discuss non-surgical choices, but it can't promise relief.

Book a free consultation: <https://comprehensive-pain-management.qckaz.com/?src=biologictherapygilbert.com>

---

Know what comes from your body before you choose.

Help with Gilbert joint soreness, home care, prepared-blood treatments, and the nearby clinic.

Help for Gilbert joint soreness, home care, and nearby choices.

This site is operated by the owners of the QC Kinetix Phoenix-area clinics, who benefit when readers book with their clinic business.

© 2026 The Gilbert Biologic Guide. General education only; personal decisions require evaluation by a qualified medical professional.